SCHEMBL1980004

SCHEMBL1980004

COc1cccc(Oc2ccc(N)cc2)c1.COc1cccc(Oc2ccc(N)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 1.00
ALDH1A1 P00352 8/20 0.80
MEN1 O00255 3/20 0.80
KMT2A Q03164 3/20 0.80
MAPT P10636 2/20 0.80
MITF O75030 1/20 0.80
GAA P10253 1/20 0.80
GFER P55789 1/20 0.80
NLRP1 Q9C000 1/20 0.80
NOD2 Q9HC29 1/20 0.80
CYP3A4 P08684 3/20 0.61
KDM4E B2RXH2 1/20 0.60
BRCA1 P38398 1/20 0.60
HBB P68871 1/20 0.60
HSD17B10 Q99714 1/20 0.60
MAOA P21397 1/20 0.59
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
NLRP3 Q96P20 1/20 0.58
TDP1 Q9NUW8 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL555032 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
Acetic Acid SCHEMBL4630370 0.90 SMN1; SMN2 (0.81) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6290623 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL562469 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6289307 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL10709191 0.89 SMN1; SMN2 (0.80) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL4092959 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6290330 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL22289568 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL1270594 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2526/4885ALDH1A1 848/4885MEN1 1190/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SMN1; SMN2 2949/4885ALDH1A1 462/4885MEN1 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.